|
Corona Remedies Limited has launched its generic version of empagliflozin introduced under the brand name “Empabite & combinations”, a SGLT-2 inhibitor for type 2 diabetes. With a commitment to affordability and accessibility, Corona Remedies will offer the medication at one-sixth (1/6th) of the price of the patent. empagliflozin is designed to improve glycaemic control in adults with T2DM, while also reducing cardiovascular outcomes in T2DM patients with CV risk and kidney diseases.
India has an estimated 10.1 crore people living with diabetes and around 15% of population which may be prediabetic. While empagliflozin has helped control blood sugar levels in addition to offering cardiovascular and renal benefits, its high cost has limited access for many patients. Corona Remedies is stepping in to bridge this gap by providing a cost-effective alternative alongside other pharmaceutical companies.
Nirav Mehta, CEO & managing director of Corona Remedies, stated, “The launch of Empabite reflects our commitment to provide affordable and effective treatment options for type 2 diabetes patients, ensuring better disease management and improved health outcomes. By making this essential treatment more accessible, we aim to improve patient outcomes and support healthcare professionals in delivering better care.”
Corona Remedies Limited was founded in 2004 and is headquartered in Ahmedabad, India. According to Pharmarack, the company is one of the Top 30 pharmaceutical firms in the country. Corona specializes in women’s health, cardiovascular care, neuropathy and pain management, respiratory, urology, bone health, and nutritional supplements.
|